Home Cart Sign in  
Chemical Structure| 1923833-60-6 Chemical Structure| 1923833-60-6

Structure of Linrodostat
CAS No.: 1923833-60-6

Chemical Structure| 1923833-60-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BMS-986205 is a specific and irreversible inhibitor of IDO1 with IC50 value of 1.7 nM.

Synonyms: BMS-986205; ONO-7701

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Linrodostat

CAS No. :1923833-60-6
Formula : C24H24ClFN2O
M.W : 410.91
SMILES Code : C[C@H]([C@H]1CC[C@@H](C2=CC=NC3=CC=C(F)C=C23)CC1)C(NC4=CC=C(Cl)C=C4)=O
Synonyms :
BMS-986205; ONO-7701
MDL No. :MFCD31729367
InChI Key :KRTIYQIPSAGSBP-KLAILNCOSA-N
Pubchem ID :121328278

Safety of Linrodostat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice SKOV3 xenograft model Oral 60 mpk QD PO Once daily Evaluate the pharmacodynamic effects of Linrodostat on kynurenine levels in the SKOV3 xenograft model PMC7883469
Mice B16F10 melanoma model Intraperitoneal injection 10-5-2-0 mg/kg/day Daily until the end of the experiment To test the effect of varying doses of Linrodostat in combination with ibrutinib on tumor growth, and found that the dose of Linrodostat correlated with anti-tumor efficacy and induction of Ly6c+CD103+ DCs. PMC8516719
Mice VPA-exposed pregnant mouse model Subcutaneous injection 5 mg/kg Single administration Linrodostat inhibited placental IDO-1 expression and reversed the protective effects of taprenepag on maternal-fetal interface homeostasis. PMC11603931

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03362411 Healthy Volunteers PHASE1 COMPLETED 2018-02-01 PPD Austin Clinic, Austin, Tex... More >>as, 78744, United States Less <<
NCT03374228 Healthy Participants PHASE1 COMPLETED 2018-02-16 Quotient Clinical, Nottingham,... More >> Ruddington Fields, NG11 6JS, United Kingdom Less <<
NCT03247283 Cancer PHASE1 COMPLETED 2017-10-15 Covance Clinical Research Unit... More >>, Inc., Madison, Wisconsin, 53704, United States Less <<
NCT03312426 Healthy Volunteers PHASE1 COMPLETED 2017-11-22 PPD Austin Clinic, Austin, Tex... More >>as, 78744, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.43mL

0.49mL

0.24mL

12.17mL

2.43mL

1.22mL

24.34mL

4.87mL

2.43mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories